<?xml version='1.0' encoding='utf-8'?>
<document id="29403319"><sentence text="A review of the pharmacology and clinical efficacy of brivaracetam."><entity charOffset="54-66" id="DDI-PubMed.29403319.s1.e0" text="brivaracetam" /></sentence><sentence text="Brivaracetam (BRV; Briviact) is a new antiepileptic drug (AED) approved for adjunctive treatment of focal (partial-onset) seizures in adults"><entity charOffset="0-12" id="DDI-PubMed.29403319.s2.e0" text="Brivaracetam" /></sentence><sentence text=" BRV is a selective, high-affinity ligand for synaptic vesicle 2A (SV2A) with 15- to 30-fold higher affinity than levetiracetam, the first AED acting on SV2A"><entity charOffset="114-127" id="DDI-PubMed.29403319.s3.e0" text="levetiracetam" /></sentence><sentence text=" It has high lipid solubility and rapid brain penetration, with engagement of the target molecule, SV2A, within minutes of administration" /><sentence text=" BRV has potent broad-spectrum antiepileptic activity in animal models" /><sentence text=" Phase I studies indicated BRV was well tolerated and showed a favorable pharmacokinetic profile over a wide dose range following single (10-1,000 mg) and multiple (200-800 mg/day) oral dosing" /><sentence text=" Three pivotal Phase III studies have demonstrated promising efficacy and a good safety and tolerability profile across doses of 50-200 mg/day in the adjunctive treatment of refractory focal seizures" /><sentence text=" Long-term data indicate that the response to BRV is sustained, with good tolerability and retention rate" /><sentence text=" BRV is highly effective in patients experiencing secondarily generalized tonic-clonic seizures" /><sentence text=" Safety data to date suggest a favorable psychiatric adverse effect profile in controlled studies, although limited postmarketing data are available" /><sentence text=" BRV is easy to use, with no titration and little drug-drug interaction" /><sentence text=" It can be initiated at target dose with no titration" /><sentence text=" Efficacy is seen on day 1 of oral use in a significant percentage of patients" /><sentence text=" Intravenous administration in a 2-minute bolus and 15-minute infusion is well tolerated" /><sentence text=" Here, we review the pharmacology, pharmacokinetics, and clinical data of BRV" /><sentence text="" /></document>